Toxic manifestations of alpelisib in endocrinology. Description of the clinical case

Breast cancer (BC) is a serious disease and is considered an important health problem worldwide. The prevalence of the disease in women according to Rosstat was 64,951 cases in the Russian Federation in 2020 (21.7% among all types of cancer).  Hormone-dependent estrogen receptor-positive (HR+), human epidermal growth factor receptor type 2 negative (HER2-) metastatic breast cancer (mBC) accounts for 70% of all cases.  About 40% of patients with ER+/HER2- mBC have mutations in the PIK3CA gene, leading to hyperactivation of the alpha isoform (p110α) of phosphatidylinositol 3-kinase (PI3K). Hormonal therapy with or without cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor is considered the standard treatment for patients with ER+/HER2- mBC. However, acquired resistance to this therapy remains a problem. Innovative methods for the treatment of breast cancer are the use of targeted therapeutic agents aimed at direct inhibition of the PI3K pathway in combination with hormone therapy. Alpelisib is a PI3Kα-specific inhibitor. Hyperglycemia is the most common side effect of alpelisib treatment. Currently, there is a consensus on the prevention and correction of hyperglycemia in patients receiving therapy with alpelisib, which recommends that before starting therapy, in  order to diagnose carbohydrate metabolism disorders and assess the risk of developing hyperglycemia, determine in all patients: the level of glycated hemoglobin (HbA1c), glucose fasting plasma (FPG), body mass index (BMI). And also to evaluate such risk factors as the presence of a family history of type 2 diabetes mellitus (DM 2), the presence of gestational diabetes in the patient’s history, or the fact of the birth of children weighing more than 4 kilograms.

Recently, new combinations of drugs have been actively used to treat disorders of carbohydrate metabolism, such as pioglitazone + metformin. This paper discusses the mechanism of action of PI3K inhibitors, new therapeutic combinations and their undesirable effects, and presents therapeutic experience.

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2020

2. Stenina M.B., Zhukova LG, Koroleva IA, et al. Practical recommendations for drug trea-tment of breast cancer. Malignant Tumors. 2020; 10 (3s2). https://rosoncoweb.ru/stan-darts/RUSSCO/2020/2020-09.pdf

3. Mazurina NV, Artamonova EV, Beloyartseva MF, et al. The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2020;22(4):56-59. doi: https://doi.org/10.26442/18151434.2020.4.200566

4. André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptorpositive, human epidermal growth factor receptor-2- negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208-217. doi: https://doi.org/10.1016/j.annonc.2020.11.011

5. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: https://doi.org/10.1200/JCO.2010.34.4879

6. Goncalves MD, Farooki A. Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. Integrative Cancer Therapies. 2022;21. doi: https://doi.org/10.1177/15347354211073163

7. Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist. 2016 Nov;21(11):1326-1336. doi: https://doi.org/10.1634/theoncologist.2015-0519

8. Семиглазова Т.Ю., Семиглазов В.В., Клименко В.В. и др. Применение алпелисиба для лечения HR+ HER2-метастатического рака молочной железы у пациентов с мутацией PIK3CA: результаты исследования SOLAR-1 // Фарматека. — 2020. — Т. 27. — №7. — С. 15-23. doi: https://doi.org/10.18565/pharmateca.2020.7.15-23

9. Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019;380:1929–40. doi: https://doi.org/10.1056/NEJMoa1813904

10. Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020;31(8):1001-10. doi: https://doi.org/10.1016/j.annonc.2020.05.001

11. Świderska E, Strycharz J, Wroblewski A, et al. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake. 2018. doi: https://doi.org/10.5772/intechopen.80402

12. Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001-1010. doi: https://doi.org/10.1016/j.annonc.2020.05.001

13. Blow T, Hyde PN, Falcone JN, et al. Treating AlpelisibInduced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211032283. doi: https://doi.org/10.1177/15347354211032283

14. Pesheva ED, Fadeev VV. Pioglitazone is a forgotten hypoglycemic drug with proven cardioprotective and nephroprotective properties. Consilium Medicum. 2021;23(4):366–371. doi: https://doi.org/10.26442/20751753.2021.4.200892